The invention provides compounds of formula
wherein R
1
, R
2
, R
3
, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
[EN] BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066<br/>[FR] DÉRIVÉS BIS-(SULFONYLAMINO) DANS UNE THÉRAPIE 066
申请人:ASTRAZENECA AB
公开号:WO2009064251A1
公开(公告)日:2009-05-22
The invention provides compounds of formula wherein R1, R3, L1, L2, G1, G2, A and m are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of microsomal prostaglandin E synthase-1.
Abstract Various polysubstituted benzofurans were reduced by using triethylsilane in trifluoracetic acid. 2,3-Dihydrobenzofurans or bibenzyl compounds were obtained in high yields, depending on the nature of the substituents at C2 and on the benzene ring of the core structure. A p-anisole substituent at C2 of benzofurans always led to the corresponding bibenzyls. Publication History Received: 09 September
PHARMACEUTICAL COMPOSITIONS AND METHODS OF PREVENTING, TREATING, OR INHIBITING INFLAMMATORY DISEASES, DISORDERS, OR CONDITIONS OF THE SKIN, AND DISEASES, DISORDERS, OR CONDITIONS ASSOCIATED WITH COLLAGEN DEPLETION
申请人:CHANG Chien-Neng
公开号:US20090010884A1
公开(公告)日:2009-01-08
The present invention provides compositions and methods for preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion using one or more estrogenic agents.
Substituted 2-phenyl benzofurans as estrogenic agents
申请人:Wyeth
公开号:US20030171428A1
公开(公告)日:2003-09-11
This invention provides estrogen receptor modulators of formula I, having the structure
1
wherein
R, R′, A, A′, X, Y, and Y are as defined in the specification, or a pharmaceutically acceptable salt thereof.